Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers.
نویسندگان
چکیده
Objective Analyze the demographics, clinical characteristics, efficacy and safety of natalizumab treatment in Brazilian patients with multiple sclerosis (MS) followed up for at least 12 months, in two tertiary MS care centers in São Paulo.Method We evaluated the effect of natalizumab treatment on annualized relapse rate and disability progression in 75 patients with MS treated with natalizumab for at least 12 months. A subgroup analysis was performed to evaluate efficacy of natalizumab treatment in patients with Expanded Disability Status Scale (EDSS) ≤ 3.0 vs patients with EDSS > 3.Results Patients treated for at least one year with natalizumab showed a 91% reduction in aRR, as well and an improvement in neurological disability. The impact of natalizumab treatment was greater in patients with EDSS < 3.0. Overall, natalizumab was safe but one patient developed progressive multifocal leukoencephalopathy.Conclusion Natalizumab as a third line therapy is safe and efficacious, especially in patients with mild neurological disability.
منابع مشابه
Oral Manifestation and Candida Albicans in Multiple Sclerosis Disease with Different Treatment Modalities
Multiple sclerosis (MS) is a chronic demyelinating disease which is considered to be an autoimmune disease impacting the central nervous system (CNS). Patients with MS may have certain orofacial manifestations and oral microbiological changes as a result of different treatment modalities. Thus, this study aimed to investigate the changes of Candida Albicans in normal oral flora during different...
متن کاملImmune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy.
OBJECTIVE To assess clinical consequences of temporary natalizumab dosage suspension. DESIGN Prospective cohort study. SETTING Multiple sclerosis (MS) center at an academic medical center in the United States. PATIENTS Thirty-two patients with MS who had received at least 12 consecutive natalizumab infusions. MAIN OUTCOMES MEASURES Recurrent MS disease activity, defined as a clinically ...
متن کاملDelivery of healthy babies after natalizumab use for multiple sclerosis: a report of two cases.
BACKGROUND In current literature, no data on safety in pregnancy for new drugs in the treatment of multiple sclerosis (MS) like natalizumab (Tysabri®), a humanized monoclonal antibody against α4 integrins, are yet available. In the management of MS, natalizumab is the first monoclonal antibody approved to the market. METHODS We describe the pregnancy and outcome in two women with MS using nat...
متن کاملFailure of natalizumab to prevent relapses in neuromyelitis optica.
OBJECTIVE To describe first experiences with the integrin inhibitor natalizumab, given to patients with suspected relapsing-remitting multiple sclerosis (MS) who were later diagnosed with aquaporin 4-positive neuromyelitis optica (NMO). DESIGN Retrospective case series. SETTING Neurology departments at tertiary referral centers in Germany. PATIENTS Patients with NMO who tested positive fo...
متن کاملNatalizumab in Multiple Sclerosis: Long-Term Management
Natalizumab is a monoclonal antibody highly effective in the treatment of relapsing remitting multiple sclerosis (RRMS) patients. Despite its effectiveness, there are growing concerns regarding the risk of progressive multifocal leukoencephalopathy (PML), a brain infection caused by John Cunningham virus (JCV), particularly after 24 doses and in patients who previously received immunosuppressiv...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Arquivos de neuro-psiquiatria
دوره 73 9 شماره
صفحات -
تاریخ انتشار 2015